Aduro Announces Pancreatic Cancer and Mesothelioma Abstracts to Be Presented at 2014 ASCO Annual Meeting
May 20, 2014 at 16:30 PM EDT
Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that two posters highlighting clinical trials of the company’s pancreatic cancer and mesothelioma immunotherapies will be presented at the upcoming American Society of Clinical Oncology (ASCO) to be held in Chicago.
The presentation will be at the following poster sessions:
Saturday, May 31, 8:00-11:45 a.m.
Sunday, June 1, 8:00-11:00 a.m.
About LADD and CRS-207
LADD is Aduro’s proprietary platform of live-attenuated double-deleted listeria monocytogenes strains that have been engineered to induce a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. CRS-207 is engineered to express mesothelin, which is expressed in pancreatic cancer, mesothelioma and other cancers.
About GVAX and GVAX Pancreas
GVAX Pancreas is one of a family of GVAX vaccines derived human cancer cell lines which are modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine. Aduro’s GVAX portfolio includes vaccines for pancreatic, prostate, colon and breast cancers as well as multiple myeloma.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a private, clinical-stage biotechnology company focused on immunotherapy for cancer. Aduro has ongoing clinical trials with its LADD platform in pancreatic cancer, mesothelioma and glioblastoma and development programs in non-small cell lung cancer, ovarian cancer and prostate cancer. The company is also developing clinical candidates using novel small molecules that activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.adurobiotech.